USE OF PKC INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION

摘要

A method for treating CMV infection and disease conditions associated therewith is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-¢N,N'-1,1'-((2"-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-butane)-bis-(3,3'-indoly1)!-1(H)-pyrrole-2,5-dione hydrochloride salt.